NYSEAMERICAN:OSTX OS Therapies Q2 2024 Earnings Report $1.56 +0.06 (+3.64%) As of 03:18 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast OS Therapies EPS ResultsActual EPS-$0.26Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOS Therapies Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOS Therapies Announcement DetailsQuarterQ2 2024Date8/14/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile OS Therapies Earnings HeadlinesOS Therapies Corporate Event Calendar | AMEX:OSTXJuly 9, 2026 | benzinga.comOS Therapies: OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST ProgramJuly 8, 2026 | finanznachrichten.deA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.July 21 at 1:00 AM | Porter & Company (Ad)OS Therapies: OS Therapies Third Quarter 2026 Corporate OutlookJuly 6, 2026 | finanznachrichten.deOS Therapies: OS Therapies Appoints Dr. Craig Eagle to Board of DirectorsJuly 2, 2026 | finanznachrichten.deOS Therapies Secures Convertible Note Financing for ExpansionJuly 2, 2026 | tipranks.comSee More OS Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OS Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OS Therapies and other key companies, straight to your email. Email Address About OS TherapiesOS Therapies (NYSEAMERICAN:OSTX), a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.View OS Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3M's Redemption Arc: Can Q2 Earnings Change the Narrative?Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of EarningsConfidence Is Back, But Earnings Show the Consumer Is Being PickyIndustrial and Utility Giants Boost Dividends as Data Center Tailwinds BuildIREN’s $2.8 Billion AI Contract Haul Changes the Stock’s StoryBuy, Hold, or Wait: 3 Small-Cap Stocks Telling Different StoriesIs Domino's Stock Serving Up a Buying Opportunity? Upcoming Earnings Tesla (7/22/2026)Freeport-McMoRan (7/22/2026)Alphabet (7/22/2026)International Business Machines (7/22/2026)ServiceNow (7/22/2026)AT&T (7/22/2026)TE Connectivity (7/22/2026)Texas Instruments (7/22/2026)United Rentals (7/22/2026)Philip Morris International (7/22/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
